Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stefano Rusconi

Showing results (81-90 of 192) with videos related to

Pageof 20
Sort By:
The New Microbiologica|January 11, 2017
Use of statins and aspirin to prevent cardiovascular disease among HIV-positive patients. A survey among Italian HIV physiciansPaolo Maggi, Giuseppe Vittorio De Socio, Stefania Cicalini, et al.
Journal of Medical Virology|September 27, 2023
HIV-DNA decrease during treatment in primary HIV-1 infection with three different drug regimens: Italian Network of Acute HIV Infection (INACTION) clinical trialElena Bruzzesi, Arianna Gabrieli, Davide Bernasconi, et al.
The Journal of Antimicrobial Chemotherapy|January 31, 2019
Durability of first-line regimens including integrase strand transfer inhibitors (INSTIs): data from a real-life settingAntonella d'Arminio Monforte, Alessandro Cozzi-Lepri, Antonio Di Biagio, et al.
Journal of the International AIDS Society|January 22, 2019
Effectiveness of dolutegravir-based regimens as either first-line or switch antiretroviral therapy: data from the Icona cohortAnnalisa Mondi, Alessandro Cozzi-Lepri, Alessandro Tavelli, et al.
AIDS Patient Care and Stds|December 7, 2017
Durability of Second Antiretroviral Regimens in the Italian Cohort Naive Antiretrovirals Foundation Study and Factors Associated with DiscontinuationAntonio Di Biagio, Patrizia Lorenzini, Giulia Gustinetti, et al.
Journal of the International AIDS Society|November 15, 2014
Treatment outcome in HIV+ patients receiving 3- or 4-drug regimens during PHIGiulia Maria Bottani, Maria Letizia Oreni, Giancarlo Orofino, et al.
Open Forum Infectious Diseases|December 20, 2017
Weight Gain: A Possible Side Effect of All AntiretroviralsLucia Taramasso, Elena Ricci, Barbara Menzaghi, et al.
The Journal of Antimicrobial Chemotherapy|January 31, 2025
Question and answers on long-acting therapy with cabotegravir and rilpivirine in people with HIVLucia Taramasso, Stefano Bonora, Antonella Cingolani, et al.
Molecules (Basel, Switzerland)|May 28, 2009
New macrocyclic amines showing activity as HIV entry inhibitors against wild type and multi-drug resistant virusesStefano Rusconi, Mirko Lo Cicero, Ottavia Viganò, et al.
BMC Infectious Diseases|January 23, 2025
Unconventional use of injectable long-acting cabotegravir and rilpivirine against HIV-1 in PWH in clinical need: 52 weeks real-world dataValentina Iannone, Roberto Rossotti, Nicholas Brian Bana, et al.
Pageof 20

Showing results (81-90 of 192) with videos related to

Sort By:
Pageof 20
The New Microbiologica|January 11, 2017
Use of statins and aspirin to prevent cardiovascular disease among HIV-positive patients. A survey among Italian HIV physiciansPaolo Maggi, Giuseppe Vittorio De Socio, Stefania Cicalini, et al.
Journal of Medical Virology|September 27, 2023
HIV-DNA decrease during treatment in primary HIV-1 infection with three different drug regimens: Italian Network of Acute HIV Infection (INACTION) clinical trialElena Bruzzesi, Arianna Gabrieli, Davide Bernasconi, et al.
The Journal of Antimicrobial Chemotherapy|January 31, 2019
Durability of first-line regimens including integrase strand transfer inhibitors (INSTIs): data from a real-life settingAntonella d'Arminio Monforte, Alessandro Cozzi-Lepri, Antonio Di Biagio, et al.
Journal of the International AIDS Society|January 22, 2019
Effectiveness of dolutegravir-based regimens as either first-line or switch antiretroviral therapy: data from the Icona cohortAnnalisa Mondi, Alessandro Cozzi-Lepri, Alessandro Tavelli, et al.
AIDS Patient Care and Stds|December 7, 2017
Durability of Second Antiretroviral Regimens in the Italian Cohort Naive Antiretrovirals Foundation Study and Factors Associated with DiscontinuationAntonio Di Biagio, Patrizia Lorenzini, Giulia Gustinetti, et al.
Journal of the International AIDS Society|November 15, 2014
Treatment outcome in HIV+ patients receiving 3- or 4-drug regimens during PHIGiulia Maria Bottani, Maria Letizia Oreni, Giancarlo Orofino, et al.
Open Forum Infectious Diseases|December 20, 2017
Weight Gain: A Possible Side Effect of All AntiretroviralsLucia Taramasso, Elena Ricci, Barbara Menzaghi, et al.
The Journal of Antimicrobial Chemotherapy|January 31, 2025
Question and answers on long-acting therapy with cabotegravir and rilpivirine in people with HIVLucia Taramasso, Stefano Bonora, Antonella Cingolani, et al.
Molecules (Basel, Switzerland)|May 28, 2009
New macrocyclic amines showing activity as HIV entry inhibitors against wild type and multi-drug resistant virusesStefano Rusconi, Mirko Lo Cicero, Ottavia Viganò, et al.
BMC Infectious Diseases|January 23, 2025
Unconventional use of injectable long-acting cabotegravir and rilpivirine against HIV-1 in PWH in clinical need: 52 weeks real-world dataValentina Iannone, Roberto Rossotti, Nicholas Brian Bana, et al.
Pageof 20